Wednesday, January 11, 2017

BRIEF-Sangamo Therapeutics receives orphan drug designation from the FDA for SB-318 genome editing treatment for MPS I

* Sangamo Therapeutics receives orphan drug designation from

the FDA for SB-318 genome editing treatment for MPS I

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)